title: Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome.
abstract: Necrolytic migratory erythema (NME), the characteristic rash associated with the glucagonoma syndrome, is a cause of substantial morbidity among patients with this rare malignancy. Treatment options are suboptimal, and often useful for only short or moderate durations. We report the effective, long-term (> 1 year) use of intermittent infusions of amino acids (AA) and fatty acids (FA) administered via peripheral intravenous access for the treatment of NME in the glucagonoma syndrome. Despite resolution of the NME, serum amino acid (initially subnormal) and fatty acid (initially normal) levels remained unchanged. Tumour growth and other symptoms related to the glucagonoma syndrome appear unaffected by such infusions.
authors.affiliation: Thyroid and Endocrine Divisions, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachussets, USA. ekalexander@partners.org
authors.forename: Erik K
authors.initials: EK
authors.lastname: Alexander
authors.forename: Malcolm
authors.initials: M
authors.lastname: Robinson
authors.forename: Maryjane
authors.initials: M
authors.lastname: Staniec
authors.forename: Robert G
authors.initials: RG
authors.lastname: Dluhy
mesh_terms: D000596:Amino Acids / Q000008:administration & dosage* / Q000097:blood; D004890:Erythema / Q000188:drug therapy* / Q000209:etiology; D005227:Fatty Acids / Q000008:administration & dosage* / Q000097:blood; D005935:Glucagonoma / Q000097:blood / Q000150:complications*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000097:blood / Q000150:complications*; D013577:Syndrome; D013997:Time Factors
chemical_list: D000596:Amino Acids; D005227:Fatty Acids